# OSENI

NDC: 64764-254
Generic name: alogliptin and pioglitazone
Labeler / Manufacturer: Takeda Pharmaceuticals America, Inc.
Product type: HUMAN PRESCRIPTION DRUG
Marketing category: New Drug Application (innovator)
Dosage form: TABLET, FILM COATED
Routes: ORAL
Marketing started: 20130125

FDA application: NDA022426

## Active ingredients

- ALOGLIPTIN BENZOATE: 25 mg/1
- PIOGLITAZONE HYDROCHLORIDE: 45 mg/1

## Pharmacological class

—

## External sources

- openFDA: https://api.fda.gov/drug/ndc.json?search=product_ndc:"64764-254"
- FDA NDC Directory: https://www.accessdata.fda.gov/scripts/cder/ndc/dsp_searchresult.cfm?p_ndc=64764-254
- DailyMed: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4c619ed9-fe3e-4158-9938-80c6c3493d55